The results of SOLD trial have been published

A phase III trial called SOLD was exploring the effect of trastuzumab duration (9 week vs 1 year as an adjuvant to standard chemotherapy) in women with early-stage HER2-positive breast cancer. The trial was conducted in 7 countries and comprising a total of 2176 patients with median follow-up of 5.2 years. 4Pharma had major role in the statistics and data management of the study. Teppo Huttunen, Senior Statistician and COO, was responsible for the statistical analysis of the study and Mikko Taalikka, Head of Data Management, supervised the data collection for the span of 10 years.

”Although the primary result of the SOLD trial was not supportive for the non-inferiority hypothesis, this has been an incredible and insightful journey to be deeply involved in the trial which is so important in the evaluation of the standard of care for one of the most common cancer”, Teppo Huttunen sorts out the statisticians role in the large scale clinical study.

See article for more details (https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589).